ISRCTN ISRCTN48210491
DOI https://doi.org/10.1186/ISRCTN48210491
Clinical Trials Information System (CTIS) 2006-003003-39
Protocol serial number N/A
Sponsor Academic Medical Center (AMC) (The Netherlands)
Funder ZonMw
Submission date
28/04/2006
Registration date
28/04/2006
Last edited
23/05/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr P.J. Hajenius
Scientific

Academic Medical Center, (AMC)
Department of Obstetrics and Gynaecology, H4-205
P.O. Box 22660
Amsterdam
1100 DD
Netherlands

Phone +31 (0)20 5663693
Email metex@amc.uva.nl

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleMethotrexate versus expectant management in women with ectopic pregnancy
Study acronymMETEX
Study objectivesTo study whether in women with suspected ectopic pregnancy with low but plateauing serum human Chorionic Gonadotropin (hCG) concentrations additional treatment with systemic methotrexate in a single dose intramuscular regimen is superior over expectant management in terms of tubal rupture, future pregnancy, health related quality of life and costs.
Ethics approval(s)1. Medical ethical committee (METC) of the Academic Medical Centre, Amsterdam, ref: 06/075
2. Central Committee on Research involving Human Subjects (CCMO), ref: NL11168.018.06, EudraCT number: 2006-003003-39
Health condition(s) or problem(s) studiedEctopic pregnancy
InterventionSystemic methotrexate in a single dose intramuscular regimen (1 mg/kg body weight) versus expectant management.
Intervention typeDrug
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Methotrexate
Primary outcome measure(s)

An uneventful decline of serum hCG to an undetectable level by primary treatment, i.e., single dose systemic methotrexate or expectant management.

Key secondary outcome measure(s)

1. Number of (re)interventions (additional methotrexate injections or surgical procedures for persistent trophoblast and/or clinical signs)
2. Treatment complications
3. Future fertility
4. Health related quality of life
5. Financial costs
6. Patients preferences

Completion date01/06/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target sample size at registration72
Key inclusion criteria1. All haemodynamically stable patients
2. greater than 18 years with either a suspected ectopic pregnancy (a visible ectopic pregnancy or an ectopic mass on Trans Vaginal Sonography) and a plateauing serum hCG concentration less than 1500 IU/l or with a Pregnancy of Unknown Location (PUL) and a plateauing serum hCG concentration less than 2000 IU/l (persisting PUL)
Key exclusion criteria1. Patients with a viable ectopic pregnancy
2. Signs of tubal rupture or active intra-abdominal bleeding
3. Abnormalities in liver or renal function or in full blood count
Date of first enrolment01/06/2006
Date of final enrolment01/06/2009

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Academic Medical Center (AMC)
Amsterdam
1100 DD
Netherlands

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/01/2013 Yes No
Results article health-related quality of life results 01/09/2015 Yes No
Protocol article protocol 19/06/2008 Yes No
Abstract results results (abstract) 01/06/2013 No No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes
Study website Study website 11/11/2025 11/11/2025 No Yes

Editorial Notes

23/05/2016: Publication reference added.